Evidence map›Paper›PMID 29391785›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2018

Economic burden of COPD in a Swedish cohort: the ARCTIC study.

Karin Lisspers, Kjell Larsson, Gunnar Johansson, Christer Janson, Madlaina Costa-Scharplatz, Jean-Bernard Gruenberger, Milica Uhde, Leif Jorgensen, Florian S Gutzwiller, Björn Ställberg

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature.The European journal of health economics : HEPAC : health economics in prevention and care · 2020
    Pooled it
  5. Trial
  6. Trial
  7. The Societal and Economic Burden of COPD in Saudi Arabia.Global journal on quality and safety in healthcare · 2026
    Article
  8. Article
  9. The Burden of COPD with Type 2 Inflammation in North-West Continental Europe.International journal of chronic obstructive pulmonary disease · 2025
    Review
  10. 20-year trends in excess costs of COPD.The European respiratory journal · 2025
    Article
  11. Article
  12. Article
  13. High use of short-acting βERJ open research · 2023
    Article
  14. Hospital Admission Rates in Patients with COPD Throughout the COVID-19 Pandemic.International journal of chronic obstructive pulmonary disease · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karin LisspersDepartment of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala.
Kjell LarssonDepartment of Work Environment Toxicology, The National Institute of Environmental Medicine, Karolinska Institute, Solna.
Gunnar JohanssonDepartment of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala.
Christer JansonDepartment of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala.
Madlaina Costa-ScharplatzNovartis AB, Täby, Sweden.
Jean-Bernard GruenbergerNovartis, Basel, Switzerland.
Milica UhdeIQVIA, Solna, Sweden.
Leif JorgensenIQVIA, Copenhagen, Denmark.
Florian S GutzwillerNovartis, Basel, Switzerland.
Björn StällbergDepartment of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We assessed direct and indirect costs associated with COPD in Sweden and examined how these costs vary across time, age, and disease stage in a cohort of patients with COPD and matched controls in a real-world, primary care (PC) setting. Patients and methods: Data from electronic medical records linked to the mandatory national health registers were collected for COPD patients and a matched reference population in 52 PC centers from 2000 to 2014. Direct health care costs (drug, outpatient or inpatient, PC, both COPD related and not COPD related) and indirect health care costs (loss of income, absenteeism, loss of productivity) were assessed. Results: A total of 17,479 patients with COPD and 84,514 reference controls were analyzed. During 2013, direct costs were considerably higher among the COPD patient population (€13,179) versus the reference population (€2,716), largely due to hospital nights unrelated to COPD. Direct costs increased with increasing disease severity and increasing age and were driven by higher respiratory drug costs and non-COPD-related hospital nights. Indirect costs (~€28,000 per patient) were the largest economic burden in COPD patients of working age during 2013. Conclusion: As non-COPD-related hospital nights represent the largest direct cost, management of comorbidities in COPD would offer clinical benefits and relieve the financial burden of disease.

Indexed as

Cost of IllnessHealth Care CostsHealth ExpendituresAbsenteeismAgedAge FactorsFemaleHumansIncomeMaleMiddle AgedModels, EconomicPrimary Health CarePulmonary Disease, Chronic ObstructiveRegistriesRetrospective StudiesburdenCOPDdirect costindirect costSweden

Identifiers

PMID29391785
PMCPMC5769573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.